Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer.

Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, Chamness GC, Reis-Filho JS, Weigelt B, Heiser LM, Hilsenbeck SG, Huang S, Rimawi MF, Gray JW, Osborne CK, Schiff R.

Mol Cancer Res. 2019 Aug 16. pii: molcanres.0756.2019. doi: 10.1158/1541-7786.MCR-19-0756. [Epub ahead of print]

PMID:
31420371
2.

Vanillic acid mitigates the ovalbumin (OVA)-induced asthma in rat model through prevention of airway inflammation.

Bai F, Fang L, Hu H, Yang Y, Feng X, Sun D.

Biosci Biotechnol Biochem. 2019 Mar;83(3):531-537. doi: 10.1080/09168451.2018.1543015. Epub 2018 Nov 13.

PMID:
30422751
3.

Inhibition of NLRP9b attenuates acute lung injury through suppressing inflammation, apoptosis and oxidative stress in murine and cell models.

Yanling Q, Xiaoning C, Fei B, Liyun F, Huizhong H, Daqing S.

Biochem Biophys Res Commun. 2018 Sep 5;503(2):436-443. doi: 10.1016/j.bbrc.2018.04.079. Epub 2018 Jun 29.

PMID:
29655793
4.

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.

Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R.

Clin Cancer Res. 2017 Sep 1;23(17):5123-5134. doi: 10.1158/1078-0432.CCR-16-2191. Epub 2017 May 9.

5.

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.

Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, Lopez-Tarruella S, Pavlick AC, Trivedi MV, Chamness GC, Chang JC, Osborne CK, Rimawi MF, Schiff R.

Clin Cancer Res. 2015 Sep 1;21(17):3995-4003. doi: 10.1158/1078-0432.CCR-14-2728. Epub 2015 May 26.

6.

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.

Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, Hu H, Schiff R, Cook RS, Kurokawa M.

Cell Cycle. 2015;14(4):648-55. doi: 10.4161/15384101.2014.994966. Erratum in: Cell Cycle. 2015;14(8):1339-41.

7.

Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy.

Goltsov A, Deeni Y, Khalil HS, Soininen T, Kyriakidis S, Hu H, Langdon SP, Harrison DJ, Bown J.

Cells. 2014 Jun 10;3(2):563-91. doi: 10.3390/cells3020563.

8.

Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.

Hu H, Goltsov A, Bown JL, Sims AH, Langdon SP, Harrison DJ, Faratian D.

Cell Signal. 2013 Jan;25(1):26-32. doi: 10.1016/j.cellsig.2012.09.014. Epub 2012 Sep 18.

PMID:
23000339

Supplemental Content

Loading ...
Support Center